Literature DB >> 8415394

Proteolysis of human growth hormone by rat thyroid gland in vitro: application of electrospray mass spectrometry and N-terminal sequencing to elucidate a metabolic pathway.

V J Wroblewski1, R E Kaiser, G W Becker.   

Abstract

The present studies were designed to provide structural characterization of peptide metabolites of biosynthetic human growth hormone (hGH) formed by rat thyroid gland proteases in vitro. Electrospray ionization mass/spectrometry (ESI-MS) and N-terminal sequencing were used to characterize the peptide metabolites. The predominant enzyme in the thyroid gland preparations was a chymotrypsin-like serine protease which was biochemically similar to rat mast cell protease-I. Metabolic intermediates were formed by cleavage of hGH exclusively at Tyr/Phe/Leu-Xaa bonds. After a 5- or 45-min incubation of hGH with thyroid gland S9 pellet fraction, the majority of metabolites formed were two-chain variants of hGH having masses ranging from 16,002 to 22,143 Da. These metabolites were formed as a result of proteolysis in the large disulfide loop region of hGH in combination with processing at Tyr42-Ser43. Based upon the time-related appearance and structural characterization of these intermediates, a sequence of metabolic events is proposed. The initial event appears to be cleavage by the chymotrypsin-like protease between Tyr143-Ser144 to form a two-chain hGH. This intermediate is then cleaved between Tyr42-Ser43, liberating the N-terminal peptide, Phe1-Tyr42. Two other metabolites were generated as a result of the deletion of the peptides Lys140-Tyr143 and Ser144-Phe146 from the large loop region. The identification of similar metabolites truncated by a single amino acid at the carboxyl terminus indicated the action of a carboxypeptidase on these metabolic products. After a 4.5-hr incubation, the protease isolated from the S9 pellet fraction degraded hGH to > 20 small peptides, having masses < or = 2300 Da.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415394     DOI: 10.1023/a:1018999730869

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  46 in total

1.  A comparison of electrospray-ionization m.s. and matrix-assisted laser desorption time-of-flight m.s. for the analysis of protein mixtures.

Authors:  M H Allen; D J Grindstaff; M L Vestal; R W Nelson
Journal:  Biochem Soc Trans       Date:  1991-11       Impact factor: 5.407

2.  Isohormones of human growth hormone. II. Plasmin-catalyzed transformation and increase in prolactin biological activity.

Authors:  R A Yadley; A Chrambach
Journal:  Endocrinology       Date:  1973-10       Impact factor: 4.736

3.  Molecular forms of circulating growth hormone during spontaneous secretory episodes and in the basal state.

Authors:  G Baumann; M W Stolar; K Amburn
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

4.  Identification of aminopeptidase activity in the secretory granules of mouse mast cells.

Authors:  W E Serafin; U A Guidry; E T Dayton; M M Kamada; R L Stevens; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

5.  Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors.

Authors:  J C Powers; T Tanaka; J W Harper; Y Minematsu; L Barker; D Lincoln; K V Crumley; J E Fraki; N M Schechter; G G Lazarus
Journal:  Biochemistry       Date:  1985-04-09       Impact factor: 3.162

6.  Lack of in vivo transformation of human growth hormone to its "activated" isohormones in peripheral tissues of the rhesus monkey.

Authors:  G Baumann; G Hodgen
Journal:  J Clin Endocrinol Metab       Date:  1976-11       Impact factor: 5.958

7.  Biochemical and clinical implications of proinsulin conversion intermediates.

Authors:  B D Given; R M Cohen; S E Shoelson; B H Frank; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Cleavage of growth hormone by rabbit liver plasmalemma enhances binding.

Authors:  J M Schepper; E F Hughes; M C Postel-Vinay; J P Hughes
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

9.  Altered proteolytic cleavage of human growth hormone as a result of deamidation.

Authors:  U J Lewis; R N Singh; L F Bonewald; B K Seavey
Journal:  J Biol Chem       Date:  1981-11-25       Impact factor: 5.157

10.  Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma.

Authors:  Y N Sinha; T A Gilligan; D W Lee; D Hollingsworth; E Markoff
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

View more
  3 in total

1.  Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI).

Authors:  S R Lang; W Staudenmann; P James; H J Manz; R Kessler; B Galli; H P Moser; A Rummelt; H P Merkle
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

2.  Characterization of a bioactive 15 kDa fragment produced by proteolytic cleavage of chicken growth hormone.

Authors:  C Arámburo; M Carranza; M Reyes; M Luna; H Martinez-Coria; L Berúmen; C G Scanes
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

3.  Proteolytic processing of human growth hormone (GH) by rat tissues in vitro: influence of sex and age.

Authors:  M Garcia-Barros; J Devesa; V M Arce
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.